Cannon Global Investment Management, LLC Corvus Pharmaceuticals, Inc. Transaction History
Cannon Global Investment Management, LLC
- $49.7 Million
- Q1 2025
A detailed history of Cannon Global Investment Management, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Cannon Global Investment Management, LLC holds 35,000 shares of CRVS stock, worth $126,700. This represents 0.22% of its overall portfolio holdings.
Number of Shares
35,000Holding current value
$126,700% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
104Shares Held
38.1MCall Options Held
2.75MPut Options Held
1.17M-
Orbimed Advisors LLC San Diego, CA6.94MShares$25.1 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$24.1 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$11.9 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$11 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$9.7 Million0.23% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $169M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...